ArticleOncotarget2020

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer.

Oliver J Pickles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.